未登录

J

Jennifer Snaith

Garvan Institute of Medical Research

H指数:8

被引数:195

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interactive online calculator for estimation of muscle and hepatic insulin sensitivity in adults with Type 1 diabetes using clinical and research biomarkers

diabetes, obesity and metabolism

IF0

2026-02-020

OAAI

Effect of metformin on insulin resistance in adults with type 1 diabetes: a 26-week randomized double-blind clinical trial

二甲双胍对1型糖尿病成人胰岛素抵抗的影响：一项26周随机双盲临床试验

Nature Communications

IF15.7

2025-11-240

OAAI

Targeting cardiometabolic risk in type 1 diabetes through incretin physiology

通过肠促胰岛素生理学靶向1型糖尿病的心血管代谢风险

trends in endocrinology and metabolism

IF0

2025-07-030

PRE

No evidence from euglycaemic–hyperinsulinaemic clamp studies for greater insulin sensitivity in adults with type 1 diabetes using insulin pump versus multiple daily insulin injections—Post hoc meta-analysis

无证据表明，与使用多次每日胰岛素注射相比，使用胰岛素泵的1型糖尿病成人具有更高的胰岛素敏感性——事后Meta分析

diabetes obesity metabolism

IF0

2025-07-010

OA

Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies

JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY

IF3.7

2024-12-240

PRE

Metformin Reduces Insulin Dose and Visceral Fat Accumulation, and Increases GDF15 without Reducing Insulin Resistance in Adults with Type 1 Diabetes-A 26-Week, Randomized, Double-Blind Placebo-Controlled Trial (INTIMET)

IF7.5

2024-06-140

PRE

Estimation of Muscle and Hepatic Insulin Sensitivity in Type 1 Diabetes Adults Using Clinical and Research Biomarkers

IF7.5

2024-06-140

PRE

Reducing Cardiometabolic Risk with Semaglutide in Type 1 Diabetes (RESET1)-A Double-Blinded Randomized Placebo-Controlled Trial (Study Protocol)

IF7.5

2024-06-140

PRE

Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial

DIABETIC MEDICINE

IF3.4

2024-06-093

OA

Sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?

MEDICAL JOURNAL OF AUSTRALIA

IF8.5

2022-06-303

OAAI

Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial

DIABETIC MEDICINE

IF3.4

2021-04-164

PREAI

Technologies in the management of type 1 diabetes

1型糖尿病的管理技术

MEDICAL JOURNAL OF AUSTRALIA

IF8.5

2021-02-281

PREAI

Letter to the Editor: Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange Registry

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

IF5.1

2020-06-171

OAAI

Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?

TRENDS IN ENDOCRINOLOGY AND METABOLISM

IF12.6

2020-02-0128

PREAI

Nesidioblastosis following laparoscopic sleeve gastrectomy

CLINICAL ENDOCRINOLOGY

IF2.4

2019-10-142

PREAI

Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2019;42:657-664

IF16.6

2019-07-121

OAAI

Excess mortality and cardiovascular disease risk in type 1 diabetes

IF88.5

2019-03-010

OAAI

A CANADIAN MULTICENTER PLACEBO-CONTROLLED STUDY OF A FIXED-DOSE OF BROFAROMINE, A REVERSIBLE SELECTIVE MAO-A INHIBITOR, IN THE TREATMENT OF MAJOR DEPRESSION

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

1994-10-0117

PREAI